Ekalia, a joint venture between IBA and Framatome, has partnered with Telix Pharmaceuticals to accelerate the production of Astatine-211, a promising alpha-emitting radioisotope used in targeted cancer therapies, in the United States. The collaboration will leverage Telix's radiopharmaceutical network to establish the first production unit at RLS Trevose in Pennsylvania, with plans to expand as demand grows. This partnership aims to build a reliable production infrastructure, enhancing patient access to innovative nuclear medicine treatments. Telix will secure long-term access to Astatine-211 to advance its alpha therapy pipeline, marking a significant step in the development of cancer treatment options.
The collaboration between Ekalia and Telix on Astatine-211 production is notable for readers following health sector developments. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 12:01 WIB: out of 150 priced US health stocks, 81 rose and 66 fell. Among notable movers, Viatris Inc (VTRS) rose 6.94% to USD 18.65, Travere Therapeutics Inc. (TVTX) fell 6.89% to USD 49.60, and Adaptive Biotechnologies Corp (ADPT) dropped 6.25% to USD 24.02.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
Telix Pharmaceuticals and Ekalia have teamed up to establish U.S.-based production of astatine-211, a rare alpha-emitting isotope used in targeted alpha therapy for cancer. This collaboration combines IBA's cyclotron technology, Framatome's nuclear e...
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
Commvault Systems is recommended as a buy due to its strong SaaS annual recurring revenue growth of 38% and decade-high profit margins. The stock is currently undervalued, trading at 27 times estimated earnings for fiscal year 2027 and 24 times for 2...
